MannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical Data

Analyst Yun Zhong from Wedbush maintained a Buy rating on MannKind (MNKD – Research Report) and keeping the price target at $11.00.

Yun Zhong has given his Buy rating due to a combination of factors related to MannKind’s inhaled insulin product, Afrezza. The analyst sees Afrezza as a significantly undervalued opportunity, particularly in light of recent clinical data.
The results from the Phase 3 INHALE-1 study in children and adolescents, along with the INHALE-3 study in adults, are expected to be presented at the ADA conference, which could further bolster Afrezza’s market adoption. Additionally, the potential for Afrezza to be used in broader patient populations adds to its growth prospects, making it an attractive investment opportunity.

In another report released on June 10, Wells Fargo also maintained a Buy rating on the stock with a $9.00 price target.